{"id":"ksi-101","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KSI-101 binds both vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG-2), two key drivers of retinal vascular dysfunction and inflammation. By blocking both pathways simultaneously, the drug aims to achieve superior anti-inflammatory and anti-vascular permeability effects compared to VEGF inhibition alone, potentially improving outcomes in wet age-related macular degeneration and diabetic retinopathy.","oneSentence":"KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:06.572Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration (wAMD)"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT06996080","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE","status":"RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2025-07-16","conditions":"Macular Edema Secondary to Inflammation","enrollment":150},{"nctId":"NCT06990399","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK","status":"RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2025-07-30","conditions":"Macular Edema Secondary to Inflammation","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tabirafusp alfa"],"phase":"phase_3","status":"active","brandName":"KSI-101","genericName":"KSI-101","companyName":"Kodiak Sciences Inc","companyId":"kodiak-sciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases. Used for Wet age-related macular degeneration (wAMD), Diabetic retinopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}